

Welcome to Reuters Legal News beta. Please enjoy and provide us with your feedback as we continue to improve the Reuters Legal News experience.



Commentary

Legal Action by Jenna Greene

January 7, 2022 6:51 PM CET Last Updated a day ago



Health

COVID-19

Public Policy



'Paramount importance': Judge orders FDA to hasten release of Pfizer vaccine docs

By Jenna Greene

4 minute read





A vial and syringe are seen in front of a displayed Pfizer and Biontech logo. REUTERS/Dado Ruvic/Illustration

< [Companies](#) [Law firms](#) [Related documents](#) >

Pfizer Inc



[See all](#)

The company and law firm names shown above are generated automatically based on the text of the article. We are improving this feature as we continue to test and develop in beta. We welcome feedback, which you can provide using the feedback tab on the right of the page.

Jan 7 - Score one for transparency.

A federal judge in Texas on Thursday ordered the Food and Drug Administration to make public the data it relied on to license Pfizer's COVID-19 vaccine, imposing a dramatically accelerated schedule that should result in the release of all information within about eight months.

That's roughly 75 years and four months faster than the FDA said it could take to complete a Freedom of Information Act request by a group of doctors and scientists seeking an estimated 450,000 pages of material about the vaccine.



[Register](#)

Register now for FREE unlimited access to Reuters.com



The court "concludes that this FOIA request is of paramount public importance," wrote U.S. District Judge Mark Pittman in Fort Worth, who was appointed to the bench by former President Donald Trump in 2019.

The FDA didn't dispute it had an obligation to make the information public but argued that its short-staffed FOIA office only had the bandwidth to review and release 500 pages a month.

While Pittman recognized "the 'unduly burdensome' challenges that this FOIA request may present to the FDA," in his four-page order, he resoundingly rejected the agency's suggested schedule.

Rather than producing 500 pages a month — the FDA's proposed timeline — he ordered the agency to turn over 55,000 a month. That means all the Pfizer vaccine data should be public by the end of the summer rather than, say, the year 2097.

Even if the FDA may not see it this way, I think Pittman did the agency — and the country — a big favor by expediting the document production.

I've been chronicling this fight since November and have heard from of readers who said they felt something was suspicious, even nefarious, in the FDA's proposed slo-mo timeline. Making the information public as soon as possible may help assuage the concerns of vaccine skeptics and convince them the product is safe.

Pittman in his order nodded to this as well, including a quote from the late senator John McCain, who said that excessive administrative secrecy "feeds conspiracy theories and reduces the public's confidence in the government."

Still, the FDA is likely to be hard-pressed to process 55,000 pages a month.



The office that reviews FOIA requests has just 10 employees, according to a declaration filed with the court by Suzann Burk, who heads the FDA's Division of Disclosure and Oversight Management. Burk said it takes eight minutes a page for a worker "to perform a careful line-by-line, word-by-word review of all responsive records before producing them in response to a FOIA request."

At that rate, the 10 employees would have to work non-stop 24 hours a day, seven days a week to produce the 55,000 pages a month (and would still fall a bit short).

But as lawyers for the plaintiffs Public Health and Medical Professionals for Transparency pointed out in court papers, the FDA as of 2020 had 18,062 employees. Surely some can be dispatched to pitch in at the FOIA office.

Aaron Siri of Siri & Glimstad, who represents the plaintiffs, in an email said the decision "came down on the side of transparency and accountability."

His clients — a group that includes more than 200 doctors, scientists, professors and public health professionals, including some who have publicly questioned the efficacy of lockdown policies, mask mandates and the vaccine itself — have pledged to publish all the information they receive from the FDA on their website.

The Justice Department, which represented the FDA in the litigation, did not immediately respond to a request for comment on Thursday evening. Pfizer, not a party to the suit, also did not immediately respond to a request for comment.

Pittman in his order made clear that the FOIA request, even if burdensome, has to be a priority for the FDA.

Quoting from remarks made during the hearing before him on December 14, he wrote that "there may not be a 'more important issue at the Food and Drug Administration . . . than the pandemic, the Pfizer vaccine, getting every American vaccinated," and assuring the public that the vaccine was not "rush[ed] on behalf of the United States."



Read more:

Wait what? FDA wants 55 years to process FOIA request over vaccine data

Register now for FREE unlimited access to Reuters.com

[Register](#)

Our Standards: [The Thomson Reuters Trust Principles.](#)

Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Jenna Greene

Jenna Greene writes about legal business and culture, taking a broad look at trends in the profession, faces behind the cases, and quirky courtroom dramas. A longtime chronicler of the legal industry and high-profile litigation, she lives in Northern California. Reach Greene at jenna.greene@thomsonreuters.com




More from Reuters



Arbery murderers
sentenced to life in
prison

Oscar-winner,

trailblazer Sidney



Poitier dies at 94

Russia is
'gaslighting' over
Ukraine conflict...



Sign up for The Daily Docket

Subscribe for our daily curated newsletter to receive the latest Reuters legal news and headlines delivered to your inbox.

[Sign up](#)

Sponsored Content

Dianomi



Trending
news on
Gold
Markets.

Sponsored
by
MarketViews



What
is the
latest
on
ETFs?
Sponsored
by
MarketViews



The latest
trends on
responsible
investing

Sponsored by
MarketViews



The latest
news on
commodity
markets
from
leading
Sponsored by
expertViews



Industry Insight

Industry Insight

The COVID-19 pandemic and the courts — Aggravation or opportunity?

December 9, 2021

Industry Insight

In-House Counsel Q&A with Erin Ziaja of NFP Corp.

December 9, 2021

Industry Insight

Global trends in legal 2021: Growth opportunities are there, but law firms will have to work for them

December 9, 2021

Diversity


How law firms increase DEI among business services and allied professionals

December 1, 2021



Sponsored Content

dianomi



Robotics
and
Artificial
Intelligence
Discover the
trends
Sponsored by
MarketViews



Discover
the latest
trends
and ideas
for
retirement
Sponsored by
MarketViews



Oil.
What
next?
Sponsored
by
MarketViews



The
Latest
Market
Thinking
From
Sponsored
by
MarketViews
Finance
Experts

Sponsored Content

dianomi



What
is the
latest
on
ETFs?
Sponsored
by
MarketViews



The latest
news on
commodity
markets
from
leading
Sponsored by
MarketViews



The latest
trends on
responsible
investing
Sponsored by
MarketViews



Trending
news on
Gold
Markets.
Sponsored
by
MarketViews



Sponsored Content

dianomi



Robotics and Artificial Intelligence
Discover the trends
Sponsored by MarketViews



Discover the latest trends and ideas for retirement planning
Sponsored by MarketViews



Oil. What next?
Sponsored by MarketViews



The Latest Market Thinking From Sponsored by MarketViews World's News Finance Experts

Latest

Home

Media

Videos

Pictures

Graphics

Browse

World

Business

Legal

Markets

Breakingviews

Technology

Investigations

Lifestyle

About Reuters



About Reuters

Careers

Reuters News Agency

Brand Attribution Guidelines

Reuters Leadership

Reuters Fact Check

Reuters Diversity Report

Stay Informed


[Download the App](#)

[Newsletters](#)

Information you can trust

Reuters, the news and media division of Thomson Reuters, is the world's largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.

Follow Us



Thomson Reuters Products

Westlaw

Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.

OneSource

The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.

Checkpoint

The industry leader for online information for tax, accounting and finance professionals.

Refinitiv Products

Refinitiv Workspace

Access unmatched financial data, news and content in a highly-customised workflow experience on desktop

Refinitiv Data Catalogue

Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts

Refinitiv World-Check

Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human

experience on desktop,
web and mobile.

relationships and human
networks.

Advertise With Us Advertising Guidelines

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

Cookies Terms of Use Privacy Corrections Site Feedback

© 2021 Reuters. All rights reserved



